This site is intended for healthcare professionals. If you are a patient or caregiver, please contact your physician to discuss clinical trial eligibility.

Advancing the research and development of highly selective medicines for pediatric and adult patients with genetically defined cancers

At Loxo Oncology, we are dedicated to the discovery and development of targeted therapies in the treatment of cancer. Our research focuses on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect—aiming to maximally inhibit the intended target. We aim to develop purpose-built, highly selective therapies designed to inhibit cancer-driving molecular targets in genetically defined pediatric and adult patient populations.

Explore our pipeline and clinical development programs, featuring highly selective compounds under evaluation in studies worldwide to determine their ability to inhibit cancer-driving molecular targets in solid tumors and hematologic malignancies.

TRK Trials logo

Tropomyosin receptor kinase (TRK) fusions are primary oncogenic drivers that can stimulate tumor growth in a wide variety of cancers.1 Clinical trials are underway to investigate the potential of highly selective TRK inhibitors to target these fusions and any potential acquired resistance to first-generation TRK inhibitors.

Learn More
RET Trials logo

Alterations in the rearranged during transfection (RET) receptor tyrosine kinase, including gene fusions and activating point mutations, represent oncogenic drivers that occur across multiple tumor types.2-9 We are currently exploring RET inhibition to assess the possibility of selectively targeting this range of oncogenic RET alterations, as well as anticipated acquired resistance mechanisms.

Learn More
globe

Sites are enrolling
all around the globe.

Find a Clinical Trial
    References:
  1. Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016;1(2):e000023.
  2. Ballerini P, Struski S, Cresson C, et al. RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation. Leukemia. 2012;26(11):2384-2389.
  3. Ju YS, Lee WC, Shin JY, et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 2012;22(3):436-445.
  4. Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012;18(3):375-377.
  5. Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18(3):382-384.
  6. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18(3):378-381.
  7. Bossi D, Carlomagno F, Pallavicini I, et al. Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies. Mol Oncol. 2014;8(2):221-231.
  8. Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. The landscape of kinase fusions in cancer. Nat Commun. 2014;5:4846.
  9. Yoshihara K, Wang Q, Torres-Garcia W, et al. The landscape and therapeutic relevance of cancer-associated transcript fusions. Oncogene. 2015;34(37):4845-4854.